Pharmapoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022

April 21st, 2015 – Navi Mumbai, India: Market Reports on India presents the report on "PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022" the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

Summary

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of GlobalData’s 2012 to 2022 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

Strong uptake of branded and generic topical calcineurin inhibitors as well as systemic vitamin derivatives will be the key growth drivers, while prescribing behavior of Indian dermatologists from GlobalData’s July 2013 survey suggests a highly crowded, genericized market.

Scope

- Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in India from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting India Atopic Dermatitis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the...